Video

Q&A With Jay Edelberg From Sanofi: Answering More Questions Since PCSK9 Approval

Author(s):

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

Jay Edelberg, MD, PhD, from Sanofi discussed how far the field has come in recent years, what it has meant to patient care so far, and what work remains to be done during the annual scientific sessions of the American Heart Association in Orlando.

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Steve Nissen, MD | Credit: Cleveland Clinic
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
© 2024 MJH Life Sciences

All rights reserved.